Monitor for any future partnership or clinical milestones; the board addition and COO promotion suggest a focus on operational execution and strategic transactions, but the filing itself contains no near-term catalyst.
ONCY drugs
ONCY drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 2 $0.9300entry
- T+1 · 6mo ago −5.38%α −4.68% · $0.8800
- T+5 · 5mo ago −12.90%α −9.94% · $0.8100
- T+20 · 5mo ago −3.15%α −1.59% · $0.9007
- T+60 · 3mo ago −8.00%α −9.12% · $0.8556
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Oncolytics Biotech announced the appointment of Stephen Glover to its Board of Directors and the promotion of John McAdory to Chief Operating Officer. This is a routine organizational change with no material financial impact.
Key Facts
- Stephen Glover appointed as independent director, granted option to purchase 96,000 shares vesting over 3 years.
- John McAdory promoted to COO, previously EVP of Strategy and Operations; no additional compensation.
- Glover brings public company board and M&A experience, including chairing Ambrx during its $2B acquisition by J&J.
Financial Impact
No financial figures disclosed; director option grant is standard compensation.
Risk Factors
- No material risks identified from this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001129928-26-000039 |
| Document: oncybodandcoo.htm | 0001129928-26-000039 |
| Document: 0001129928-26-000039-index-headers.html | 0001129928-26-000039 |
| Document: 0001129928-26-000039-index.html | 0001129928-26-000039 |
| Document: 0001129928-26-000039.txt | 0001129928-26-000039 |
Track record
32 reports on ONCY
3 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +10.53% at T+5 after the Apr 6, 2026 report. 7 of 12 went positive at some point.
Filters
- Nov 13, 20263d ago Press Release Neutral 3/10 Entry $0.3700 Now $0.3400 −8.11% settles Dec 14
- Nov 12, 20264d ago 8-K Neutral 3/10 Entry $0.3720 Now $0.3400 −8.60% settles Dec 11
- Nov 11, 20265d ago Press Release Neutral 3/10 Entry $0.3720 Now $0.3400 −8.60% settles Dec 11
- Nov 9, 20267d ago 8-K Neutral 3/10 Entry $0.4077 Now $0.3400 −16.61% settles Dec 8
- Nov 9, 20267d ago Press Release Neutral 3/10 Entry $0.4077 Now $0.3400 −16.61% settles Dec 8
- Nov 4, 202612d ago 8-K Neutral 4/10 Entry $0.4248 Now $0.3400 −19.96% settles Dec 3
- Nov 4, 202612d ago Press Release Bullish 6/10 Entry $0.4248 Now $0.3400 −19.96% settles Dec 3
- Oct 27, 202620d ago 8-K Bullish 6/10 Entry $0.4623 Now $0.3400 −26.45% settles Nov 24
- Oct 27, 202620d ago Press Release Bullish 6/10 Entry $0.4623 Now $0.3400 −26.45% settles Nov 24
- Oct 20, 202627d ago 8-K Neutral 3/10 Entry $0.4986 Now $0.3400 −31.81% settles Nov 17
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers